New EPA Cancer Risk Guidelines Receiving Favorable Reactions

Favorable Reactions Researchers and industry representatives are reacting positively to the Environmental Protection Agency's (EPA) recently proposed revised guidelines for carcinogen risk assessment. That approval is somewhat tempered by warnings sounded by environmental and consumer-education groups regarding the interpretation of certain suggestions in the long-awaited document. OPPORTUNITY: The revisions encourage use of new data notes Bernard Goldstein. The guidelines, released in mid-

Written byKaren Young Kreeger
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

Favorable Reactions Researchers and industry representatives are reacting positively to the Environmental Protection Agency's (EPA) recently proposed revised guidelines for carcinogen risk assessment. That approval is somewhat tempered by warnings sounded by environmental and consumer-education groups regarding the interpretation of certain suggestions in the long-awaited document.

OPPORTUNITY: The revisions encourage use of new data notes Bernard Goldstein. The guidelines, released in mid-April, incorporate recommendations from several scientific review boards and a National Academy of Sciences panel on changing EPA's methods for assessing human cancer risk from pollutants and industrial chemicals (see story on page 7). The document calls for infusing modern molecular biological information, such as how a chemical may alter DNA, into the agency's 10-year-old policy for measuring toxicity. EPA currently relies on experiments in which rodents are exposed to high doses of chemicals. The measurement practice, which has been a subject of much scientific and regulatory debate, is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies